NCT01882829View on ClinicalTrials.gov

Nuedexta in Treatment-Resistant Major Depression

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Major Depressive DisorderTreatment Resistant
Interventions
DRUG

dextromethorphan/quinidine

up to 45/10 mg every 12 hours in patients with TRD with a short 7 day tapering period in which subjects are tapered off 45/10 mg dose from twice a day to once daily for an additional 7 days at post 8-week treatment period to minimize the potential for discontinuation effects

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

James Murrough

OTHER

NCT01882829 - Nuedexta in Treatment-Resistant Major Depression | Biotech Hunter | Biotech Hunter